Search results | Galderma

You searched for: «【✈️ Telegram ID: KPU77】 대성피 성인 피시방 안전 보장 100% 알거래 중개소 리스트 - 용인»

Fort Worth’s Galderma, Maker of Cetaphil, Presents the 5th Annual Wonder Run 5K and Kids 1K to Benefit Children’s Skin Disease Foundation

Cetaphil Products Essential for Children with Both Moderate Skin Conditions and Severe Skin Diseases

Galderma announces the launch of FACE by Galderma™ – a game-changing augmented reality solution helping healthcare professionals grow their activity and improve patient satisfaction

FACE by Galderma™ is a cutting-edge aesthetic visualization application that simulates the results of injectable treatments in real time, using digital facial assessment
The application provides advanced wrinkle detection as well as the possible results of 19 injectable treatments, which are displayed as dynamic “before and afte

Galderma to present extensive new clinical data across its portfolio of neuromodulators, fillers and biostimulators at the IMCAS World Congress 2022

Strong clinical data supporting Alluzience^® (abobotulinumtoxinA, ABO), the first liquid, ready-to-use neuromodulator as an effective and well-tolerated treatment for glabellar (frown) lines, with a rapid onset and long duration of action of up to six months
Data confirming that Dysport^® was consistently efficacious for the treatment of frown lines, was wel

IMCAS 2026: Galderma showcases the latest scientific advances behind the industry’s broadest injectable aesthetics portfolio

At IMCAS 2026, Galderma will present findings supporting Sculptra’s^® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas^1-7
Multiple studies will reinforce

IMCAS 2025: Galderma’s broad presence and new data on recently launched products Restylane® SHAYPE™ and Relfydess® reaffirm its category leadership

Galderma will present new data on Relfydess (RelabotulinumtoxinA) – the first and only ready-to-use liquid neuromodulator created using PEARL™ Technology, which has now launched in multiple countries in Europe – including results from the phase IIIb RELAX trial, reinforcing its long-term efficacy and high patient satisfaction, as seen in the READY clinical trial program^1-7